Trial Profile

Evaluation of Safety and Durable Immunogenicity of Melanoma Vaccination, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 12 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Peptide vaccines (Primary) ; Peptide vaccines (Primary) ; Varlilumab (Primary) ; Montanide ISA-51; Montanide ISA-51; Poly ICLC; Poly ICLC
Indications Malignant melanoma
Focus Adverse reactions; Pharmacodynamics
Acronyms Mel-65

Most Recent Events

02 Feb 2024 Status changed from recruiting to completed.
03 Apr 2023 Planned End Date changed from 8 Feb 2023 to 8 Sep 2024.
03 Apr 2023 Planned primary completion date changed from 1 Feb 2023 to 1 Sep 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com